Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Trial details
- Registry ID
- NCT04869943
- Phase
- Phase 3
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Mestane
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 | VERU | Phase 3 | Terminated | 2024-01-09Actual |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 | OLMA | Phase 3 | Active not recruiting | 2026-10-31Estimated |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |